Taniguchi Rieko, Muramatsu Hideki, Okuno Yusuke, Suzuki Kyogo, Obu Satoshi, Nakatochi Masahiro, Shimamura Teppei, Takahashi Yoshiyuki, Horikoshi Yasuo, Watanabe Kenichiro, Kojima Seiji
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26823. Epub 2017 Sep 17.
Donor cell leukemia (DCL) occurs after allogeneic hematopoietic stem cell transplantation. Several mechanisms, including occult leukemic/preleukemic subclones in the donor graft and germline predisposition to leukemia, are proposed to be associated with DCL's molecular pathogenesis. We report a comprehensive genetic analysis of a patient with KMT2A-rearranged DCL after allogeneic bone marrow transplantation for refractory cytopenia of childhood.
We performed a whole-exome sequencing of the recipient's peripheral blood before transplant and the donor's peripheral blood and the recipient's bone marrow at the time of DCL diagnosis. RNA sequencing was also performed to detect fusion genes in DCL blasts.
There were no germline mutations that were associated with a predisposition to leukemia in the recipient and donor. Furthermore, there were no detectable somatic alterations except KMT2A-MLLT10 and other related gene fusions in DCL. KMT2A-MLLT10 was not detectable in the donor's bone marrow.
We propose a novel pattern of the molecular pathogenesis of DCL solely involving a genetic mutation acquired after transplant with no identifiable genetic factor related to the donor and recipient.
供体细胞白血病(DCL)发生于异基因造血干细胞移植后。包括供体移植物中隐匿的白血病/白血病前期亚克隆以及白血病的种系易感性在内的多种机制被认为与DCL的分子发病机制有关。我们报告了一例儿童难治性血细胞减少症患者在接受异基因骨髓移植后发生KMT2A重排的DCL的全面基因分析。
我们对移植前受者外周血、DCL诊断时供者外周血和受者骨髓进行了全外显子测序。还进行了RNA测序以检测DCL原始细胞中的融合基因。
受者和供者均未发现与白血病易感性相关的种系突变。此外,除了DCL中的KMT2A-MLLT10和其他相关基因融合外,未检测到体细胞改变。在供者骨髓中未检测到KMT2A-MLLT10。
我们提出了一种DCL分子发病机制的新模式,即仅涉及移植后获得的基因突变,而没有可识别的与供者和受者相关的遗传因素。